Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Follicular Lymphoma Excellence Forum

Follicular Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Daniel Landsberg, MD
Conference Coverage
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Joanna Rhodes, MD
Conference Coverage
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Lymphoma, Leukemia & Myeloma Network
Peter Martin, MD
Conference Coverage
04/06/2024

Featuring Peter Martin, MD

Featuring Peter Martin, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates &...
04/06/2024
Oncology
Lorenzo Falchi, MD
Conference Coverage
01/12/2024
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
David Andorsky, MD
Conference Coverage
01/10/2024
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Alexey Danilov, MD
Conference Coverage
01/10/2024
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Emanuele Zucca, MD
Conference Coverage
12/20/2023
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting,...
12/20/2023
Oncology
Tycel Phillips, MD
Conference Coverage
12/10/2023
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Quiz
12/07/2023
True or False: According to a 7-year follow-up of the phase 3 SELENE study, the overall survival in the ibrutinib-chemotherapy arm and placebo chemotherapy arm were promising, which indicates encouraging outcomes among patients in the second...
True or False: According to a 7-year follow-up of the phase 3 SELENE study, the overall survival in the ibrutinib-chemotherapy arm and placebo chemotherapy arm were promising, which indicates encouraging outcomes among patients in the second...
True or False: According to a...
12/07/2023
Oncology
Gilles Salles, MD, PhD
Videos
11/27/2023
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD,...
11/27/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement